Formycon AG reports €19.5 million revenue for first nine months of 2025
Formycon AG reported revenues of €19.5 million for the first nine months of 2025, down from €41.1 million in 2024, due to a shift from one-time license payments to sales from commercialized products. The company posted an EBITDA of €-21.7 million and a net result of €-21.4 million. Working capital increased to €83.2 million, aided by a €70 million corporate bond. Formycon confirmed its full-year EBITDA guidance and anticipates a positive EBITDA by 2026 or 2027, with key developments in biosimilars in the US and Europe.
Formycon AG reported revenues of €19.5 million for the first nine months of 2025, compared to €41.1 million in the same period of 2024, reflecting a temporary decline due to the transition from one-time license payments to a higher share of sales from commercialized products. The company posted an EBITDA of €-21.7 million, down from €2.9 million in the previous year’s period, and a net result of €-21.4 million, compared to €-17.7 million in 2024. Working capital increased to €83.2 million from €65.8 million, supported by the successful placement of a €70 million corporate bond maturing in July 2029. Formycon confirmed its full-year EBITDA guidance of between €-20 million and €-10 million and expects a positive EBITDA ideally in 2026, but no later than 2027. Key business developments included continued market penetration of the Stelara biosimilar FYB202 in the US and Europe, the launch of the ranibizumab biosimilar FYB201 pre-filled syringe in Europe, a settlement and license agreement with Regeneron for the aflibercept biosimilar FYB203 in the US, and regulatory progress for the pembrolizumab biosimilar candidate FYB206, which advanced without requiring a Phase III study. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2228876_en), on November 13, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
